about
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapyUnsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia.A Class of Semiparametric Mixture Cure Survival Models with Dependent Censoring.A Gaussian Copula Model for Multivariate Survival DataAdjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaSouthwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia GroupPhase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignmentInfluence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemiaChange point-cure models with application to estimating the change-point effect of age of diagnosis among prostate cancer patients.Impact of body-mass index on the outcome of adult patients with acute myeloid leukemiaRandomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Impact of residual normal metaphases in core binding factor acute myeloid leukemiaElevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experienceCure models as a useful statistical tool for analyzing survival.Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
P50
Q30835785-6BA6571C-19D5-4331-9B3A-88E87D516E0FQ33601710-8A12DBB2-7B1E-4A76-8456-1E4DC29A666CQ33781722-28D88D0B-97D1-42D0-92A5-A0C90B8560A5Q33981864-0A56C7E0-F777-4C0F-A757-2DFE50FFFED3Q34060554-E87641A0-7253-45B1-AF65-CDE646CC0D92Q34097546-3C0B7465-0FF4-4B6A-9F81-D47851E2652DQ34289273-7C5F1BA6-7CCF-40B9-A17C-CD1D4D2C02B3Q34302258-2C4C3622-33AA-4948-824A-F4641278B031Q34318490-524D325F-F9B6-470A-B2AF-9CC529D28C1FQ34404280-C4E0788A-C74D-4B78-A9C3-3573D951D973Q34484199-14746FEA-CAC7-45A8-A52B-BB07C0E4F299Q34504963-B118E0A6-435E-4962-8BFD-6908B4C0D416Q34587614-0FB52ED5-07EF-4DDD-81BE-90C8183A5909Q35007792-93234328-BE39-4820-AF0F-F0C20329B4E5Q35146284-4C86CED9-8E36-40E9-805B-A57F6BB9E5BAQ35164246-A4C934DD-B3C7-4B2E-9057-391B65EEDB35Q35215042-721C674F-CC1A-472C-8F41-3F32CE39D1DDQ35285004-E02E7192-8603-471B-A09C-777D4930271EQ35343940-ECE9EDC5-7B9D-4ED9-B9AA-068BAAB4DBC3Q35565648-0462978C-21F4-4660-A7F3-CE8DC673DA1BQ35671452-C0BC8E99-13A8-4A53-B8F4-9334A93A469DQ35915720-2A504A55-67B8-4B1D-9410-26D544B62B46Q36216242-A30301BB-5637-4AC5-AB51-4A2128E543A1Q36347314-E02F8BCA-950C-4D88-8DFD-01DA4C6208EDQ36366636-D63118B9-25A5-4479-9768-EB1909063EB1Q36375411-4473954E-80D3-444E-B485-9C9FC860CB34Q36467544-E65DFCAC-3829-44B3-892F-BF62B3FD8E0EQ36478979-22D91DAC-D749-4612-A195-4A3F74CBCCD6Q36483114-E5C919E3-617F-4D7A-A2F7-8CB58967207DQ36485407-30482042-182F-4206-B9E8-890FD7AB4271Q36655704-072ACB31-C16D-4B56-B966-73C66E7DEF03Q36730404-F9504423-5BD9-46DD-963C-F0C2704040BCQ36914475-77362502-4DB8-49CF-A4D4-4472BF046A71Q37006786-000B9E27-0A30-446D-B04A-853D28E74F52Q37096671-C94FDB54-E787-4E58-842E-D522FB0D830DQ37158771-E901E8B6-9101-4698-8EB0-C5B6DECA83A4Q37311249-8FDCBA49-6583-4385-883D-951AEDC8EB3BQ37324869-929E970C-12F3-46F3-BEFB-EC3659A0C425Q37392513-5BA3A200-BACE-4BD7-8D8E-4DC7D1DF53FEQ37529635-A7CB2C6A-0E1F-43B4-9DD0-3288F911A3EC
P50
name
Megan Othus
@en
Megan Othus
@nl
type
label
Megan Othus
@en
Megan Othus
@nl
prefLabel
Megan Othus
@en
Megan Othus
@nl